RecruitingPhase 1NCT07479667

An Antibody-armored Dendritic Cell in Patients With Solid Tumors

An Exploratory, Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Antibody-armored Dendritic Cell Injection Following a Single Administration in Patients With Solid Tumors

Sponsor

Shanghai Cell Therapy Group Co.,Ltd

Enrollment

8 participants

Start Date

Feb 5, 2026

Study Type

INTERVENTIONAL

Conditions

Adjuvant Therapy Solid Cancers

Summary

This study is a single-arm, open-label, single-administration dose-escalation study.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Armored Dendritic Cell Injection for people with adjuvant therapy and solid cancers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 80 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.